Showing results (81-90 of 444) with videos related to
Sort By:
Pageof 45
Expert Opinion on Investigational Drugs|November 29, 2021
COVID-related fibrosis: insights into potential drug targetsGiacomo Sgalla, Alessia Comes, Marialessia Lerede, et al.Expert Opinion on Emerging Drugs|March 18, 2011
Emerging drugs for idiopathic pulmonary fibrosisMoisés Selman, Annie Pardo, Luca Richeldi, et al.Journal of Medical Case Reports|July 9, 2016
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case reportStefania Cerri, Giacomo Sgalla, Luca Richeldi, et al.Expert Review of Respiratory Medicine|December 12, 2018
Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosisRiccardo Inchingolo, Francesco Varone, Giacomo Sgalla, et al.International Archives of Occupational and Environmental Health|December 14, 2006
Room size is the major determinant for tuberculin conversion in health care workers exposed to a multidrug-resistant tuberculosis patientAlberto Franchi, Luca Richeldi, Giovanni Parrinello, et al.Current Opinion in Pulmonary Medicine|July 5, 2012
The big clinical trials in idiopathic pulmonary fibrosisFabrizio Luppi, Paolo Spagnolo, Stefania Cerri, et al.Orphanet Journal of Rare Diseases|October 19, 2012
Genetic testing in diffuse parenchymal lung diseasePaolo Spagnolo, Fabrizio Luppi, Stefania Cerri, et al.Seminars in Respiratory and Critical Care Medicine|February 18, 2009
Environmental triggers and susceptibility factors in idiopathic granulomatous diseasesPaolo Spagnolo, Luca Richeldi, Roland M du BoisExpert Review of Respiratory Medicine|February 9, 2016
Novel drug targets for idiopathic pulmonary fibrosisGiacomo Sgalla, Elisabetta Cocconcelli, Roberto Tonelli, et al.Expert Opinion on Pharmacotherapy|June 4, 2024
Promising advances in treatments for the management of idiopathic pulmonary fibrosisCarmelo Sofia, Alessia Comes, Giacomo Sgalla, et al.Pageof 45